What's new

Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 21, Status: Authorised

Jun 2, 2025 - 15:00
 0
Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 21, Status: Authorised
Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 21, Status: Authorised
Read More

Tags:

Previous Article

STAT+: Pharmalittle: We’re reading about Sanofi buying Blueprint, a Bristol deal...

Next Article

Human medicines European public assessment report (EPAR): Xofluza, baloxavir mar...

Related Posts

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR...

May 27, 2025  0

Human medicines European public assessment report (EPAR): Enbrel, etanercept, Date of authorisation: 02/02/2000, Revision: 75, Status: Authorised

Human medicines European public assessment report (EPAR...

May 13, 2025  0

Product Management Service (PMS) information day 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 21 May 2025, 09:00 (CEST) to 21 May 2025, 17:30 (CEST)

Product Management Service (PMS) information day 2025, ...

May 26, 2025  0